Showing 1631-1640 of 1732 results for "".
- New Recommendations on Glucocorticoid Treatment for People with Neuromuscular Disordershttps://practicalneurology.com/news/new-guidelines-published-for-glucocorticoid-treatment-for-people-with-neuromuscular-disorders/2474507/A multidisciplinary expert panel has released new consensus-based recommendations on glucocorticoid use for people with neuromuscular disorders, aiming to streamline clinical decisions amid a lack of specific, formal guidelines. Published in Muscle and Nerve, the guidance aims to support safer, m
- Nasal Powder Approved by FDA for Treatment of Adults with Acute Migrainehttps://practicalneurology.com/news/nasal-powder-approved-by-fda-for-treatment-of-adults-with-acute-migraine/2474441/The Food and Drug Administration (FDA) has approved Atzumi (dihydroergotamine [DHE]; Satsuma Pharmaceuticals, Durham, NC) for the treatment of adults with acute migraine with or without aura. Atzumi is a powder formulation designed for intranasal drug delivery via a squeezable device. FDA
- The FDA Approves a Once-Daily Medication for Treating Hyperphagia Caused by Prader-Willi Syndromehttps://practicalneurology.com/news/the-fda-approves-a-once-daily-medication-for-treating-hyperphagia-caused-by-prader-willi-syndrome/2473822/The Food and Drug Administration (FDA) has approved Vykat XR (diazoxide choline [DCCR] extended-release tablets; Soleno, Redwood City, CA) for the treatment of hyperphagia in people with Prader-Willi syndrome (PWS) aged 4 years and older. Vykat XR is an extended-release formulation of DCCR, a cry
- Switching to SC Kesimpta from IVAnti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/Switching-SC-Kesimpta-IVAnti-CD20-Therapies-Safe-Effective-Across-Diverse-Individuals-Relapsing-MS/2471739/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Associations Between NfL Concentrations and Cognitive and Radiologic Outcomes Revealed in Study of Individuals with RMS Treated with Zeposiahttps://practicalneurology.com/news/associations-between-relapsing-ms-treatment-with-zeposia-nfl-concentrations-and-cognitive-and-radiologic-outcomes-revealed-in-1-year-interim-analysis-data/2473801/Research presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that neurofilament light chain (NfL) may be a useful biomarker for both cognitive and radiologic outcomes in early relapsing multiple sclerosis (RMS). The findings resul
- Study Identifies Significant Variations in Pediatric MOGAD Treatmenthttps://practicalneurology.com/news/study-identifies-significant-variations-in-pediatric-mogad-treatment/2473800/The results of a study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 found significant variations in how neurologists treat pediatric individuals with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Res
- Switching to SC Kesimpta from IV Anti-CD20 Therapies is Safe, Effective Across Diverse Individuals with Relapsing MShttps://practicalneurology.com/news/kesimpta-maintains-efficacy-across-race-and-ethnic-groups-in-relapsing-ms-patients-transitioning-from-intravenous-anti-cd20-therapies/2473797/Study results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that treatment with Kesimpta (ofatumumab; Novartis, Cambridge, MA) maintained efficacy across ethnic and racial groups in individuals with relapsing multiple sclero
- Enhanced EDSS Instrument Helpful in Assessing Disability Progression in People with MShttps://practicalneurology.com/news/researchers-develop-modified-edss-tool-for-improved-measurement-of-pira-in-ms/2473795/In a recent study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025, a novel assessment tool for measuring multiple sclerosis (MS) disease progression showed utility for redefining and quantifying progression independent of relapse acti
- Study Examines Effects of Tenecteplase Following Reperfusion for Strokehttps://practicalneurology.com/news/study-examines-effects-of-tenecteplase-following-reperfusion-for-stroke/2473773/Treatment with intra-arterial TNKase (tenecteplase; Genentech, South San Francisco, CA) after successful endovascular thrombectomy (EVT) for people with acute ischemic stroke (AIS) due to large vessel occlusion did not significantly increase the likelihood of freedom from disability. The results
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder